NCT00569127 2026-03-18
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
63 trialsNCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT07262957 2025-12-22
PANENCA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT02457156 2025-03-13
PANasta
University of Liverpool
Phase 3 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04871204 2024-10-31
OTIS
Karolinska University Hospital
Phase 2 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02381249 2023-11-27
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
St. James's Hospital, Ireland
Phase NA Completed
NCT02385617 2023-11-27
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
St. James's Hospital, Ireland
Phase NA Completed
NCT06080204 2023-10-18
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Phase NA Completed
NCT06085976 2023-10-17
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003057 2023-06-18
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003283 2023-06-15
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT05682209 2023-01-18
The Effect of Octreotide on Wound Drainage After Mastectomy
University College Hospital, Ibadan
Phase 4 Completed
NCT04027348 2022-11-29
Palliative Management of Inoperable Malignant Bowel Obstruction
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01229943 2022-08-04
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT03791736 2022-07-28
SANDOSTATINE
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT03734627 2021-08-16
EndoGut
St. James's Hospital, Ireland
Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT04129255 2020-09-10
CSMS99
National Cancer Institute, Naples
Phase 2 Completed
NCT00002864 2020-04-01
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00226967 2020-01-27
Stress, Diurnal Cortisol, and Breast Cancer Survival
Stanford University
Completed
NCT04140409 2019-10-25
SCIROCCO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 4 Terminated
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT03057509 2019-06-21
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Phase 1 Withdrawn
NCT03812939 2019-01-23
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
Peking Union Medical College Hospital
Unknown
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT00182754 2017-04-11
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00332969 2017-03-31
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Novartis
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT00002779 2016-12-15
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02920567 2016-09-30
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion
Saint Vincent's Hospital, Korea
Phase NA Unknown
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00033605 2016-07-13
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00075868 2015-11-17
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated